<DOC>
	<DOCNO>NCT00989001</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy vernakalant injection subject recent onset ( AF &gt; 3 hour &lt; = 7 day ) , symptomatic atrial fibrillation evidence history congestive heart failure .</brief_summary>
	<brief_title>A Phase 3b Study Vernakalant Injection Patients With Recent Onset Symptomatic Atrial Fibrillation ( AF ) ( MK-6621-045 )</brief_title>
	<detailed_description>Participants receive 10-minute intravenous ( IV ) infusion vernakalant ( 3 mg/kg ) equivalent amount normal saline ( placebo ) , follow 15-minute observation period . If participant still atrial fibrillation atrial flutter , second 10-minute IV infusion vernakalant ( 2 mg/kg ) equivalent amount placebo administer unless participant experience dose-stopping criterion start first infusion . If participant convert sinus rhythm first second infusion , infusion complete .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Females must pregnant nursing premenopausal , must use effective form birth control time screen 30 day post study treatment Subject must recent onset ( &gt; 3 hour &lt; = 7 day ) symptomatic AF best manage acute conversion SR Subject must adequate anticoagulant therapy Subject must systolic blood pressure ( SBP ) 90 mmHg less 160 mmHg diastolic blood pressure ( DBP ) less 95 mmHg screen baseline Subject must body weight 45 136 kg , inclusive ( 99 300 lb ) Subject history heart failure documentation leave ventricular dysfunction Subject know suspect prolonged QT uncorrected QT interval &gt; 0.440 sec Subject symptomatic bradycardia ventricular rate le 50 bpm Screening , unless control pacemaker Subject bradycardia ( heart rate le 50 bpm ) hypotension ( SBP le 90 mmHg ) receive loading , bolus dose , sustained infusion rate control medication Screening Subject QRS interval &gt; 0.14 sec. , unless subject pacemaker Subject myocardial infarction ( MI ) , acute coronary syndrome , cardiac surgery ( include percutaneous transluminal coronary angioplasty ( PTCA ) stent placement ) , within 30 day prior enrollment subject evidence new ischemic change Screening 12lead ECG Subject troponin I T level beyond upper limit normal local lab Subject significant valvular stenosis , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy constrictive pericarditis Subject fail electrical cardioversion AF anytime Subject fail pharmacologic conversion intravenous Class I Class III antiarrhythmic drug episode AF Subject know reversible cause AF alcohol intoxication , pulmonary embolism , hyperthyroidism , acute pericarditis hypoxemia Subject uncorrected electrolyte imbalance Subject clinical evidence digoxin toxicity Subject history clinically significant illness ( e.g . neurological , gastrointestinal , renal , hepatic , pulmonary , metabolic , endocrine , hematological , psychiatric ) , medical condition laboratory abnormality within 4 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>RSD1235</keyword>
	<keyword>Vernakalant</keyword>
	<keyword>conversion</keyword>
</DOC>